Organogenesis Holdings Inc.
Health
Performance
7.8
Risk
Sell
Buy
Curious about the Scores? Learn more.

Organogenesis Holdings Inc. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

23.07.2026
Off life support. Still risky, but slightly less scary.
16.07.2026
Danger zone. Balance sheet’s flashing red across the board.
27.06.2026
Rock bottom. The fall’s complete, stability nowhere to be found.
27.06.2026
Momentum tanked. Clearly underperforming.
ORGO
Organogenesis Holdings Inc.
2.47
-7.84%
7.8
Sell
Buy
Organogenesis Holdings Inc.

Organogenesis Holdings Inc. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Organogenesis Holdings Inc. do? Business model and key facts

Get the full picture of Organogenesis Holdings Inc.: what it builds, where it operates, and how it makes money.

Organogenesis Holdings Inc. Profile

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees (FY): 854

Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.

shop
Company facts
Gary S. Gillheeney
CEO
854
Employees worldwide
shop
Performance
-48.76%
Last 12 months
-83.42%
Last 5 years
shop
Growth
$563.03M
Revenue year
$37.03M
Net income
shop
Valuation
$337.13M
Market Cap
32.38
Price/Earnings Ratio

Stocks related to Organogenesis Holdings Inc.

Selected based on industry alignment and relative market positioning.

EOLS
Evolus, Inc.
5.89
+1.46%
8.2
Sell
Buy
Evolus, Inc.
KMDA
Kamada Ltd.
7.01
-3.71%
4.0
Sell
Buy
Kamada Ltd.
EVO
Evotec SE
1.95
-2.50%
9.0
Sell
Buy
Evotec SE
SNDL
SNDL Inc.
1.27
-1.55%
7.1
Sell
Buy
SNDL Inc.
SIGA
SIGA Technologies, Inc.
3.39
-5.31%
8.6
Sell
Buy
SIGA Technologies, Inc.

Events and news impacting Organogenesis Holdings Inc. stock

Earnings, coporate decisions and industry developments that can affect the share price.

Organogenesis Holdings Inc. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.